This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Efficacy and Safety of Growth Hormone Treatment in Children Born Small for Gestational Age in Japan
Growth-promoting effects and safety of growth hormone ( GH ) treatment in prepubertal short-statured children born small for gestational age ( SGA ) were evaluated in a multicenter , open-label , r and omized parallel-group comparison study . Patients were r and omized to two dose groups ; 34 and 33 patients received GH at 0.033 and 0.067 mg/kg/day for one year , respectively . The increase of the mean height velocity st and ard deviation score ( SDS ) was significantly ( p < 0.0001 ) higher in the 0.067-mg group ( from -1.4 to 4.7 ) than that in the 0.033-mg group ( -1.9 to 2.6 ) . A significant ( p < 0.0001 ) increase in the mean height SDS was established in the 0.067-mg group ; increases of -3.1 to -2.5 vs -3.1 to -2.2 in the 0.033- and 0.067-mg groups , respectively . The trial was non-eventful . Oral glucose tolerance tests indicated a mostly normal pattern of plasma glucose before and after 12-month GH treatment . The growth-promoting effect was significantly higher with GH treatment at 0.067 mg/kg/day
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .